Navigation Links
Nile Therapeutics, Inc. Completes $1.34 Million Registered Direct Offering
Date:4/4/2012

SAN MATEO, Calif., April 4, 2012 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it has completed its previously announced sale of an aggregate of 3.35 million shares of its common stock and warrants to purchase an additional 2,512,500 shares of common stock at an initial exercise price of $0.50 per share.  The total gross proceeds from the registered direct offering were $1.34 million, before deducting selling commissions and expenses of approximately $0.2 million.

The company plans to use the net proceeds from the offering for general corporate purposes, including funding its activities related to planning and designing its next Phase 2 clinical trial of cenderitide. 

Roth Capital Partners, LLC acted as sole placement agent in the offering.

The securities were sold pursuant to a shelf registration statement (File No. 333-165167), which was declared effective by the United States Securities and Exchange Commission ("SEC") on March 12, 2010. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A prospectus supplement relating to the offering has been filed with the SEC.  Copies of the prospectus supplement and the accompanying base prospectus may be obtained at the SEC's website at www.sec.gov.

About Post-Acute Heart Failure

Heart failure is the fastest-growing clinical cardiac disease in the U.S. according to the American Heart Association, affecting over 5 million Americans. Over 1 million
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Md. and TORONTO , May ... announced today that John Mon , Chief ... MicroCap Conference on Thursday, May 30, 2013 in ... The Company,s presentation is scheduled to begin ... live webcast. To access the webcast, go to:   http://wsw.com/webcast/marcum/mfs.v/ ...
(Date:5/22/2013)... 22, 2013  BD (Becton, Dickinson and Company) (NYSE: ... company, announced today the publication of its 2012 ... and it continues to focus on the Company,s shared ... the principles of shared value — creating value for ... societies — are fundamental to our strategy," said ...
(Date:5/22/2013)... 22, 2013 Cellular Biomedicine Group (OTCQB: CBMG) today ... the total projected enrollment required for its Phase I trial ... Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), ... trial has had no Severe Adverse Effect (SAE) reported. ... HCC, registered with NIH under number NCT01828762 (click here ...
Breaking Medicine Technology:Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 2Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 3BD Issues 2012 Sustainability Report 2BD Issues 2012 Sustainability Report 3Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer 2Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer 3
... FRANCISCO, Sept. 27, 2011 HEALTH 2.0 -- Brain ... to improve brain function, launched MyCalmBeat – a personal ... MyCalmBeat optimally decreases stress and increases focus through slow breathing ... widely known that slow, deep breathing is one of the best ...
... Nearly three quarters of the medical technology market in ... but the next wave of growth is likely to come ... the India market, according to preliminary findings of a study ... today at AdvaMed 2011, the annual MedTech conference in Washington, ...
Cached Medicine Technology:Brain Resource Launches MyCalmBeat Personal Stress Reduction Monitor at Health 2.0 2Brain Resource Launches MyCalmBeat Personal Stress Reduction Monitor at Health 2.0 3Made in India, for India, is Next Wave of Growth for Region's Medical Technology Sector 2Made in India, for India, is Next Wave of Growth for Region's Medical Technology Sector 3
(Date:5/22/2013)... 2013 Ethos Spa Skin and Laser ... for the busy lifestyle of the modern man and woman. ... for the occasion, whether it is for an anniversary or ... any other occasion. , Clients should know that they have ... designs on the Ethos Spa’s website, ranging from abstract ...
(Date:5/22/2013)... Margate City, NJ (PRWEB) May 22, 2013 ... from solved. In some states, up to twenty-seven percent ... half of all bankruptcies of private citizens in the U.S. ... medical care also affects prescription drugs, meaning that many patients ... doctor, or even get them filled at all. That's ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Beginning Aug. ... in the Conrad Foundation’s Spirit of Innovation Challenge ... technical plan competition, free and open to students ages ... The Spirit of Innovation Challenge celebrates the life and ... walk on the Moon. The program challenges teens to ...
(Date:5/22/2013)... The 2013 release of the Diagnostic and Statistical Manual ... the field of mental health in over 20 years and ... release with a Webinar tonight at 8PM ET. An entire ... scheme besides the now obsolete DSM-4. On May 27, 2013 ... honor of this event, Dr. Steven Buser and the Asheville ...
(Date:5/22/2013)... May 22, 2013 Abadir Associates, a ... treatments for optimal results, is offering a new technique ... neck. The practice has successfully treated multiple patients ... “Basically, this approach is for women who want to ... dermatologist Dr. Michelle Abadir of Abadir Associates. ...
Breaking Medicine News(10 mins):Health News:Ethos Spa Skin And Laser Center Has Launched Their Customizable Gift Certificates 2Health News:Lyrica Discount Cards Now Available From MedicationDiscountCard.com 2Health News:Conrad Foundation Announces 2013-2014 Spirit of Innovation Challenge Launch Date 2Health News:What You Need to Know About DSM-5: The Asheville Jung Center is Hosting a Webinar Tonight on the New Material in DSM-5 2Health News:Westchester Dermatologist Abadir Associates Offers New Neck Lift Surgery Alternative 2
... Challenge the Status Quo of U.S. Health Care,System, According ... WASHINGTON, July 30 More than 750,000,Americans left the ... projected to grow to six million by 2010, potentially ... retail clinics in operation,has also soared by 220 percent ...
... Budget Surplus in New Mexico Provides Additional Opportunity for Universal, ... New Report ... from HealthLeaders-InterStudy, NASHVILLE, Tenn., July 30 ,HealthLeaders-InterStudy, ... July 2008 announcement of a nearly $400,million revenue windfall for ...
... YORK (July 30, 2008) -- Robotic surgery, largely ... adapted for use in other areas, including for ... Cornell Medical Center now have significant experience -- ... for removal of the bladder, also known as ...
... PARIS, July 30 The French agency Agence ... 10 million dollars from the Bill &,Melinda Gates ... Committees in Africa and Asia. These Committees will ... to implement,vaccination policy and programs adapted to their ...
... to Include Two ACRO Representatives, WASHINGTON, July ... and the Metrics Champion Consortium,(MCC) are pleased to ... the MCC Board of Directors. In an agreement ... MCC, a multidisciplinary organization,whose mission is to develop ...
... CYT, MONTREAL, July 30 /PRNewswire-FirstCall/ - CryoCath (TSX: CYT), will,hold ... 9:00 a.m. (Eastern Time) on Tuesday, August 5, 2008. The call ... Ginette Gagne, CFO.,The Company will report its results in a press ... DATE: ...
Cached Medicine News:Health News:Explosive Growth in Medical Tourism and Rise of Retail Clinics Provide Huge Cost Savings for Patients 2Health News:Explosive Growth in Medical Tourism and Rise of Retail Clinics Provide Huge Cost Savings for Patients 3Health News:Explosive Growth in Medical Tourism and Rise of Retail Clinics Provide Huge Cost Savings for Patients 4Health News:Explosive Growth in Medical Tourism and Rise of Retail Clinics Provide Huge Cost Savings for Patients 5Health News:Gov. Richardson's Healthcare Reform Agenda Gains New Life 2Health News:Robotic surgery extends benefits to bladder cancer patients at NewYork-Presbyterian/Weill Cornell 2Health News:French Agency Receives 10 Million Dollar Grant From the Bill & Melinda Gates Foundation to Support the Establishment of National Vaccine Advisory Committees in Africa and Asia 2Health News:French Agency Receives 10 Million Dollar Grant From the Bill & Melinda Gates Foundation to Support the Establishment of National Vaccine Advisory Committees in Africa and Asia 3Health News:MCC Names ACRO Leaders to Board of Directors 2Health News:CryoCath to Hold Third Quarter 2008 Conference Call and Webcast 2
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
Medicine Products: